326 related articles for article (PubMed ID: 15312350)
1. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y; Zhang XR; Fu J; Tan W; Zhang W
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
3. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.
Harpole DH; Herndon JE; Wolfe WG; Iglehart JD; Marks JR
Cancer Res; 1995 Jan; 55(1):51-6. PubMed ID: 7805040
[TBL] [Abstract][Full Text] [Related]
4. [Study of prognostic factors in patients with stage I non-small cell lung cancer].
Jiang ZQ; Jiang GL; Shi DR; Zhang RX; Fu XL; Qian H
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):364-8. PubMed ID: 15312349
[TBL] [Abstract][Full Text] [Related]
5. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
7. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
8. Combined expression of p53, Bcl-2, and p21WAF-1 proteins in lung cancer and premalignant lesions: association with clinical characteristics.
Kalomenidis I; Orphanidou D; Papamichalis G; Vassilakopoulos T; Scorilas A; Rasidakis A; Papastamatiou H; Jordanoglou J; Roussos C
Lung; 2001; 179(5):265-78. PubMed ID: 11976895
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer.
Shibata Y; Hidaka S; Tagawa Y; Nagayasu T
Anticancer Res; 2004; 24(3b):1925-8. PubMed ID: 15274378
[TBL] [Abstract][Full Text] [Related]
10. Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.
Prenzel KL; Baldus SE; Mönig SP; Tack D; Sinning JM; Gutschow CA; Grass G; Schneider PM; Dienes HP; Hölscher AH
Cancer; 2004 May; 100(9):1909-17. PubMed ID: 15112272
[TBL] [Abstract][Full Text] [Related]
11. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer.
Borner MM; Brousset P; Pfanner-Meyer B; Bacchi M; Vonlanthen S; Hotz MA; Altermatt HJ; Schlaifer D; Reed JC; Betticher DC
Br J Cancer; 1999 Feb; 79(5-6):952-8. PubMed ID: 10070896
[TBL] [Abstract][Full Text] [Related]
12. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
[TBL] [Abstract][Full Text] [Related]
14. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
15. p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review.
Haque AK; Adegboyega P; Al-Salameh A; Vrazel DP; Zwischenberger J
Mod Pathol; 1999 Dec; 12(12):1158-66. PubMed ID: 10619270
[TBL] [Abstract][Full Text] [Related]
16. [Significance of fatty acid synthase expression in non-small cell lung cancer].
Wang Y; Zhang X; Tan W; Fu J; Zhang W
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):271-3. PubMed ID: 12515624
[TBL] [Abstract][Full Text] [Related]
17. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
19. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu oncogene and estrogen receptor expression in non small cell lung cancer patients.
Alerić I; Razumović JJ; Koprivica B
Med Pregl; 2012; 65(5-6):210-5. PubMed ID: 22730705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
